Drug Trial Radar · NCT04871711
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
487
Actual
Start
May 10, 2021
Primary completion
Oct 31, 2022
Study completion Oct 31, 2022
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a 16-week study in adult participants with chronic hand eczema (CHE). \> The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. \> The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.
Conditions
- Chronic Hand Eczema
Interventions
Delgocitinib creamDrug
Cream for topical application
Cream vehicleDrug
The cream vehicle is similar to the delgocitinib cream\> except that it does not contain any active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With IGA-CHE TS at Week 16Time frame: 16 weeks
Locations
54 sites in 6 countries. Site status is shown where the registry gives one.
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Edmonton, Alberta, Canada
LEO Investigational Site
Edmonton, Alberta, Canada
LEO Investigational Site
Red Deer, Alberta, Canada
LEO Investigational Site
Kingston, Ontario, Canada
LEO Investigational Site
London, Ontario, Canada
LEO Investigational Site
Markham, Ontario, Canada
LEO Investigational Site
Toronto, Ontario, Canada
LEO Investigational Site
Montreal, Quebec, Canada
LEO Investigational Site
Bordeaux, France
LEO Investigational Site
Dijon, France
LEO Investigational Site
Lorient, France
LEO Investigational Site
Martigues, France
LEO Investigational Site
Nice, France
LEO Investigational Site
Paris, France
LEO Investigational Site
Toulouse, France
LEO Investigational Site
Nice, Alpes-Maritimes, France
LEO Investigational Site
Reims, Ardennes, France
LEO Investigational Site
Nantes, Loire-Atlantique 6, France
LEO Investigational Site
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
LEO Investigational Site
Lille, Nord, France
LEO Investigational Site
Le Mans, Sarthe, France
LEO Investigational Site
Berlin, Germany
LEO Investigational Site
Dresden, Germany
LEO Investigational Site
Gera, Germany
LEO Investigational Site
Göttingen, Germany
LEO Investigational Site
Hamburg, Germany
LEO Investigational Site
Haßfurt, Germany
LEO Investigational Site
Mainz, Germany
LEO Investigational Site
Memmingen, Germany
LEO Investigational Site
München, Germany
LEO Investigational Site
Osnabrück, Germany
LEO Investigational Site
Brescia, Italy
LEO Investigational Site
L’Aquila, Italy
LEO Investigational Site
Milan, Italy
LEO Investigational Site
Perugia, Italy
LEO Investigational Site
Roma, Italy
LEO Investigational Site
Vicenza, Italy
LEO Investigational Site
Bialystok, Poland
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.